Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Urinary Bladder Neoplasms 2Ureteral Neoplasms 2Carcinoma, Transitional Cell 2Urothelial Cancer 1Urologic Neoplasms 1Urethral Neoplasms 1Triple Negative Breast Neoplasms 1Metastatic Urothelial Cancer 1Head and Neck Neoplasms 1Esophageal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

Gemcitabine 5Cisplatin 4enfortumab vedotin 2Ramucirumab 2Platinum 2Docetaxel 21,2-diaminocyclohexaneplatinum II citrate 2vinflunine 1rucaparib 1pembrolizumab 1eribulin 1enzalutamide 1dehydroftorafur 1carotuximab 1avelumab 1atezolizumab 1Standard of Care 1Specimen Handling 1Radiotherapy 1Radiation 1Paclitaxel 1N-(3-aminopropyl)-N-(1-(5-benzyl-3-methyl-4-oxo-(1,2)thiazolo(5,4-d)pyrimidin-6-yl)-2-methylpropyl)-4-methylbenzamide 1Mitozytrex 1Mitomycin 1Magnetic Resonance Spectroscopy 1Interleukin-7 1Immunoglobulin G 1Icrucumab 1IMC-18F1 1Fluorouracil 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Ureteral Neoplasms × enfortumab vedotin × Clear all
NCT03474107 2026-01-09

A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)

Astellas Pharma Inc

Phase 3 Completed
608 enrolled 22 charts 1 FDA
Genitourinary

Urinary Bladder Neoplasms, Ureteral Neoplasms

NCT03219333 2024-08-27

EV-201

Astellas Pharma Inc

Phase 2 Completed
219 enrolled 32 charts 2 FDA
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms, Urologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡